All Online

1 - 12 of 15 results

Refine

Active filters

Cardiovascular Risk in Diabetes
1 CME CREDIT

Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/26/2020, and they are subject to change as new information is published.


0.58 CME CREDIT

During this session (part 3 of 3 from webcast series), Dr. Aguilar and Dr. Thethi review data from cardiovascular outcomes trials for SGLT2 inhibitors and use a patient case to discuss the American Diabetes Association guidelines for individualizing diabetes therapy for patients with ASCVD, heart failure and chronic kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.


0.75 CME CREDIT

During this session (part 2 of 3 from webcast series), Dr. Aguilar and Dr. Thethi review data from cardiovascular outcomes trials for GLP-1 RAs and DPP-4 inhibitors. Using 2 patient cases, they discuss the American Diabetes Association guidelines for individualizing diabetes therapy for patients with ASCVD, heart failure, and chronic kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.


0.25 CME CREDIT

During this session (part 1 of 3 webcast videos), Dr. Tina Thethi reviews the association between type 2 diabetes and cardiovascular disease as well as provides an overview of the American Diabetes Association guidelines designed to help individualize therapy for patients with T2DM and concurrent heart failure and/or atherosclerotic cardiovascular disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.


1 CME CREDIT

Over ten percent of the U.S. population suffers disproportionate cardiometabolic risk because of their type 2 diabetes (T2DM). In light of recent data, GLP-1 receptor agonists (GLP-1 RAs) have taken on a more prominent role in T2DM management algorithms. This session will discuss how you can distinguish among GLP-1 RAs and use them in your practice to help manage the risks that these patients face beyond glucose control. A member of the Diabetes Sisters organization will also be joining us to discuss their experience with starting a GLP-1 RA as a patient.


Cardiovascular Risk in T2DM

1.50 CME/MOC
1.48 AANP | 1.13 Pharmacology


0.25 CME CREDIT

GLP-1 Receptor Agonists: A Cardiology Perspective (Podcast)

0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology

In this podcast, cardiologist Ty Gluckman will take a deep dive into the cardiology benefits of glucagon like peptide-1 receptor agonists (GLP-1 RA). He will review the clinical trial data which has resulted in GLP-1 RA incorporation into guidelines, which address patients who have both diabetes and atherosclerotic cardiovascular disease. Dr. Gluckman will bring the perspective of a cardiologist into the discussion of these agents with emerging significance in cardiovascular risk reduction.


0.5 CME CREDIT

In this clinical coffee break, cardiologist Ty Gluckman and endocrinologist Archana Sadhu will explain why glucagon like peptide-1 receptor agonists (GLP-1 RA) are becoming increasingly prominent in diabetes algorithms and cardiovascular risk reduction. Faculty will review the clinical trial data on this class of medications as well as the mechanisms by which GLP-1 RA provide cardiovascular benefit. You will have the opportunity to engage with this activity, viewing resources and testing your knowledge with interactive questions and cases.


1 CME CREDIT

As the incidence of diabetes and obesity continue to grow, more Americans will develop serious complications and experience premature mortality from cardiometabolic causes. This session will enable you to stay up to date on recent groundbreaking research and management guideline updates that could change the way you treat your patients with diabetes, obesity, and/or dyslipidemia.


0.25 CME CREDIT

GLP-1 Receptor Agonists: Overcoming Barriers (Podcast)

0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology

With the growing role of GLP-1 RAs in the management of diabetes, primary care providers are likely to find themselves discussing this class of medications with their patients. In this podcast, Dr. Michelle Magee will focus on barriers that patients may face to starting a GLP-1 RA and common questions that emerge in patient teaching. Faculty will review ways to troubleshoot these challenges and empower the clinician to engage in effective dialogue around this drug class. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 11/18/2020 and they are subject to change as new information is published.


0.5 CME CREDIT

Jeopardy! GLP-1 RA Edition

0.50 CME
0.41 AANP | 0.41 Pharmacology

Think you know it all about GLP-1 receptor agonists? Test your familiarity with these dynamic diabetes drugs in Jeopardy game show. This interactive game will allow you to showcase your knowledge on GLP-1 RA pharmacodynamics, clinical indications, cardiovascular benefits, and more. There will be a rationale following each question, ensuring that you have answers to take back to your practice. Please note that any data, indications, and guidelines presented in this activity are current as of 08/14/20 and they are subject to change as new information is published.


0.5 CME CREDIT

Jeopardy! Using GLP-1 RAs in the Clinic

0.50 CME/MOC
0.50 AANP | 0.50 Pharmacology

Step into the clinic and onto the game show floor! In this interactive game of Jeopardy! test your knowledge of GLP-1 RAs in various patient encounters where you can implement your knowledge of type 2 diabetes management algorithms and use shared decision with patients. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 09/30/2020 and they are subject to change as new information is published.